Effect of Concomitant Use of Potassium Binders on Oral Opioid Dosage and Pain Scale: A Single-Institution Retrospective Cohort Study

Although potassium binders may reduce the absorption of orally administered cationic opioids in the intestinal lumen, their clinical impact is unknown. This study aimed to clarify the effects of the concomitant use of potassium binders on opioid dosage and analgesic efficacy. A single-institution retrospective cohort study was conducted with 112 adult patients who received oral opioids and initiated potassium binders. The primary outcome was a change in the maximum scheduled opioid dose before and after potassium binder initiation. Oxycodone-equivalent doses (strong opioid cohort) and tramadol doses (weak opioid cohort) were compared. Factors associated with strong scheduled opioid dose escalation were assessed using univariate logistic regression. Of the 112 patients, 66 patients comprised the strong opioid cohort and 46 patients comprised the weak opioid cohort. In the strong opioid cohort, the maximum scheduled opioid dose significantly increased after potassium binder initiation (p = 0.022), whereas no significant change was observed in the weak opioid cohort (p = 0.978). Univariable logistic regression identified age <65 years (odds ratio [OR]: 3.71; 95% confidence interval [CI]: 1.06-15.2; p = 0.040), aspartate aspartate aminotransferase (OR: 1.02; 95% CI: 1.01-1.04; p = 0.013), and oxycodone-equivalent scheduled doses ≥25 mg/d (OR: 4.45; 95% CI: 1.25-16.6; p = 0.022), particularly ≥80 mg/d (OR: 7.66; 95% CI: 1.70-37.4; p = 0.009) as factors associated with scheduled dose escalation. Concomitant use of potassium binders may be associated with reduced strong opioid analgesic efficacy. Age <65 years, elevated aspartate aminotransferase and oxycodone-equivalent scheduled doses ≥25 mg/d were considered factors associated with scheduled opioid dose escalation.

Authors

Institutions

Publication Details

Journal
Biological and Pharmaceutical Bulletin
Published
2026-11-18
DOI
https://doi.org/10.1248/bpb.b26-00418
Primary Topic
Pain Management and Opioid Use
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Effect of Concomitant Use of Potassium Binders on Oral Opioid Dosage and Pain Scale: A Single-Institution Retrospective Cohort Study

Yumi Takeguchi, Takuya Iwamoto, Yusuke Nakatani, Hideo Kato et al.
1 links
Biological and Pharmaceutical Bulletin
Pain Management and Opioid Use
article

Effect of Concomitant Use of Potassium Binders on Oral Opioid Dosage and Pain Scale: A Single-Institution Retrospective Cohort Study

Yumi Takeguchi, Takuya Iwamoto, Yusuke Nakatani, Hideo Kato, Akiharu Okamoto, Yuki Asai, Takako Matsubara
article en

Abstract

Although potassium binders may reduce the absorption of orally administered cationic opioids in the intestinal lumen, their clinical impact is unknown. This study aimed to clarify the effects of the concomitant use of potassium binders on opioid dosage and analgesic efficacy. A single-institution retrospective cohort study was conducted with 112 adult patients who received oral opioids and initiated potassium binders. The primary outcome was a change in the maximum scheduled opioid dose before and after potassium binder initiation. Oxycodone-equivalent doses (strong opioid cohort) and tramadol doses (weak opioid cohort) were compared. Factors associated with strong scheduled opioid dose escalation were assessed using univariate logistic regression. Of the 112 patients, 66 patients comprised the strong opioid cohort and 46 patients comprised the weak opioid cohort. In the strong opioid cohort, the maximum scheduled opioid dose significantly increased after potassium binder initiation (p = 0.022), whereas no significant change was observed in the weak opioid cohort (p = 0.978). Univariable logistic regression identified age <65 years (odds ratio [OR]: 3.71; 95% confidence interval [CI]: 1.06-15.2; p = 0.040), aspartate aspartate aminotransferase (OR: 1.02; 95% CI: 1.01-1.04; p = 0.013), and oxycodone-equivalent scheduled doses ≥25 mg/d (OR: 4.45; 95% CI: 1.25-16.6; p = 0.022), particularly ≥80 mg/d (OR: 7.66; 95% CI: 1.70-37.4; p = 0.009) as factors associated with scheduled dose escalation. Concomitant use of potassium binders may be associated with reduced strong opioid analgesic efficacy. Age <65 years, elevated aspartate aminotransferase and oxycodone-equivalent scheduled doses ≥25 mg/d were considered factors associated with scheduled opioid dose escalation.

Biological and Pharmaceutical BulletinVol. 49(11)
Mie University Hospital (JP)
Good health and well-being
Pain Management and Opioid Use
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon